

# Tillotts Pharma Transfers of Value in 2015 to Swiss Healthcare Professionals and Healthcare Organisations

Date of publication: June 2016

	Full Name  (Art. 1.01)	HCPs: City of Principal Practice HCOs: city where registered  (Art. 3)	Country of Principal Practice  (Schedule 1)	Principal Practice Address  (Art. 3)	Donations and Grants to HCOs (Art. 3.01.1.a)	Contribution to costs of Events (Art. 3.01.1.b & 3.01.2.a)			Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.c)			
						Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the contract, including travel & accommodation relevant to the contract		
HCPs	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)											
	Prof. Dr. med. Dr. phil. Gerhard Rogler	Zürich	Switzerland	UniversitätsSpital Zürich, Rämistrasse 100, 8006 Zürich	N/A	N/A				CHF 5'500	CHF 7'162	
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons											
	Aggregate amount attributable to transfers of value to such Recipients					N/A	N/A				CHF 4385	
	Number of Recipients in aggregate disclosure					N/A	N/A				1	
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02					N/A	N/A				50%		
HCOs	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)											
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons											
	Aggregate amount attributable to transfers of value to such Recipients											
	Number of Recipients in aggregate disclosure											
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02												
R & D	AGGREGATE DISCLOSURE											
	Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1										CHF 14'261	

## **Methodological Notes**

### **Disclosure by Tillotts Pharma of payments to Swiss healthcare professionals and healthcare organisations in 2015**

The Code of conduct of the pharmaceutical industry in Switzerland on cooperation with healthcare professional circles and patient organizations (Pharma Cooperation Code) mandates the public disclosure in 2016 of certain transfers of value made during 2015 to Swiss healthcare professionals and healthcare organisations. The disclosure data will be published on the website of Tillotts Pharma, [www.tillotts.com](http://www.tillotts.com). The disclosure requirements are set forth in Section 2 of the Pharma Cooperation Code.

The methodological notes below explain the data Tillotts Pharma have disclosed and how the data have been prepared, to assist the reader's understanding. Inclusion of these methodological notes alongside the disclosure data is mandated by Articles 281 – 282 of the Pharma Cooperation Code.

#### **VAT**

VAT is excluded from all disclosures of transfer of value.

#### **Currency**

All disclosures are made in Swiss Francs (CHF). Where the original payment was made in Euros, the sum was converted to Swiss Francs at the 2015 average annual exchange rate published by the European Central Bank.

#### **Consolidated Disclosures of the Corporate Group and Cross-border Payments**

The disclosures represent the consolidated transfers of value made by the Tillotts Pharma corporate group in line with the EFPIA Disclosure Code's dictate that separate entities belonging to the same multinational company (which could be the parent company and subsidiary company) shall be deemed to constitute a single company. In 2015, all transfers of value represent payments made by Tillotts Pharma AG.

#### **Multi-year contracts**

Where multi-year contracts are included in the disclosure of transfer of value made by Tillotts Pharma in 2015, the disclosures related to these multi-year contracts represent the services rendered and paid for in 2015, and/or any expenses incurred and paid for in 2015, in each case under such contracts. In one instance, expenses are disclosed as they were incurred and paid for in 2015, but the related fee for service was not paid for in 2015 as the invoice was not received until 2016. As such fee for service was paid in 2016, it will be disclosed as part of the next reporting cycle in 2017.

#### **Data included**

The data disclosed by Tillotts Pharma is consistent with the requirements of the Pharma Cooperation Code. The data can be categorised as follows:

##### *Payment of consultants who provide services to Tillotts Pharma*

Disclosed data includes the payment of honoraria to Swiss healthcare professionals who provided services to Tillotts Pharma during 2015. Where applicable, the disclosure data also includes payment of reasonable expenses to such consultants incurred in the delivery of their services, such as travel

expenses and/or accommodation expenses. Where permission to disclose transfers of value on an individual basis was not obtained from an individual health professional, the transfers of value made to such healthcare professional are disclosed in an aggregated fashion.

*Research & Development*

Transfers of value representing financial support for research and development (including the planning and performance of non-clinical studies (subject to the *OECD Principles on Good Laboratory Practice*)), as well as costs that are subsidiary to these activities, are disclosed in an aggregated fashion.